Seasonal Variation in COPD Exacerbations: a Post-Hoc Analysis from the KRONOS Phase III Study of Budesonide/Glycopyrrolate/ Formoterol Fumarate Metered Dose Inhaler (BGF MDI)

被引：0
|
作者：
Rabe, K. F. [1 ,2 ]
Fabbri, L. M. [3 ]
Martinez, F. J. [4 ]
Ferguson, G. T. [5 ]
Bourne, E. [6 ]
Darken, P. [6 ]
DeAngelis, K. [6 ]
Aurivillius, M. [7 ]
Reisner, C. [7 ]
Dorinsky, P. [6 ]
机构：
[1] Lungenclin Grosshansdorf GmbH, Zentrum Pneumol & Thoraxchirurg, Grosshansdorf, Germany
[2] Deutsch Zentrum Lungenforsch Dzl, Airway Res Ctr North Arcn, Giessen, Germany
[3] Sahlgrens Univ Hosp, Gothenburg, Sweden
[4] Joan & Sanford I Weill Dept Med, New York, NY USA
[5] Pulm Res Inst Southeast Michigan, Farmington Hills, MI USA
[6] Pearl Astrazeneca, Durham, NC USA
[7] Astrazeneca, Cambridge, England
来源：
PNEUMOLOGIE | 2020年 / 74卷
关键词：
D O I：
10.1055/s-0039-3403160
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
P488
引用
收藏
页码：S44 / S44
页数：1
相关论文
共 50 条
  • [31] Bone Mineral Density and Ocular Safety After 52 Weeks' Treatment with Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Using Co-Suspension Delivery Technology in COPD
    Kerwin, E. M.
    Ferguson, G. T.
    Mo, M.
    DeAngelis, K.
    Dorinsky, P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [32] COPD exacerbation rates by month in the ETHOS trial with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels
    Martinez, Fernando J.
    Rabe, Klaus F.
    Ferguson, Gary T.
    Wang, Chen
    Singh, Dave
    Wedzicha, Jadwiga A.
    Trivedi, Roopa
    St Rose, Earl
    Ballal, Shaila
    Mclaren, Julie
    Darken, Patrick
    Aurivillius, Magnus
    Reisner, Colin
    Dorinsky, Paul
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [33] Estimated lifetime effectiveness of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) versus dual LAMA/LABA and ICS/LABA therapies in moderate-to-very severe COPD
    Polyzoi, Maria
    Treharne, Catrin
    Mccrea, Charles
    Arnetorp, Sophie
    de Nigris, Enrico
    Holmgren, Ulf
    Miller, Paul
    Varghese, Precil
    Haughney, John
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [34] Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Improves Lung Function in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies
    Martinez, F. J.
    Rabe, K. F.
    Lipworth, B. J.
    Arora, S.
    Jenkins, M.
    Maes, A.
    Martin, U. J.
    Reisner, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [35] Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts (vol 22, 187, 2021)
    Muro, Shigeo
    Sugiura, Hisatoshi
    Darken, Patrick
    Dorinsky, Paul
    RESPIRATORY RESEARCH, 2021, 22 (01)
  • [36] Frequent Productive Cough in COPD Patients Without Exacerbation History Is Associated With Increased Risk of Exacerbations and a Treatment Benefit From Budesonide/Glycopyrrolate/Formoterol Fumarate: A Post Hoc Analysis of Kronos
    Marshall, J.
    Martinez, F. J.
    Ferguson, G. T.
    Mushunje, A.
    Bowen, K.
    Jenkins, M.
    Patel, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [37] Budesonide/glycopyrrolate/ formoterol fumarate metered dose inhaler, formulated using co-suspension delivery technology, improves lung function and exacerbation outcomes in patients with COPD without a recent history of exacerbations: subgroup analysis of KRONOS study
    Martinez, F. J.
    Ferguson, G. T.
    Bourne, E.
    Ballal, S.
    Darken, P.
    DeAngelis, K.
    Aurivillius, M.
    Dorinsky, P.
    Reisner, C.
    PNEUMOLOGIE, 2020, 74 : S44 - S44
  • [38] BUDESONIDE/GLYCOPYRROLATE/FORMOTEROL FUMARATE METERED DOSE INHALER, FORMULATED USING CO-SUSPENSION DELIVERY TECHNOLOGY, IMPROVES LUNG FUNCTION AND EXACERBATION OUTCOMES IN PATIENTS WITH COPD WITHOUT A RECENT HISTORY OF EXACERBATIONS: SUBGROUP ANALYSIS OF KRONOS STUDY
    Martinez, Fernando
    Ferguson, Gary
    Bourne, Eric
    Ballal, Shaila
    Darken, Patrick
    Deangelis, Kiernan
    Aurivillius, Magnus
    Dorinsky, Paul
    Reisner, Colin
    CHEST, 2019, 156 (04) : 2276A - 2277A
  • [39] Glycopyrrolate/formoterol fumarate metered dose inhaler for maintenance-naive patients with chronic obstructive pulmonary disease: a post-hoc analysis of the randomized PINNACLE trials
    Zheng, Jinping
    Xu, Jin-fu
    Jenkins, Martin
    Assam, Pryseley Nkouibert
    Wang, Lijiao
    Lipworth, Brian J.
    RESPIRATORY RESEARCH, 2020, 21 (01)
  • [40] A 12-52 Week (Variable Length) Randomized Double-Blind Study of Budesonide/Formoterol Fumarate Metered Dose Inhaler (BFF MDI) Compared with Formoterol Fumarate (FF) MDI in COPD (SOPHOS)
    Hanania, N. A.
    Papi, A.
    Anzueto, A.
    Martinez, F. J.
    Rossman, K.
    Cappelletti, C.
    Duncan, E. A.
    Nyberg, J.
    Dorinsky, P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
12345